Radiation Therapy for Metastatic Gastrointestinal Cancers
This study is looking at how radiation therapy works for people with gastrointestinal cancers (like esophageal or stomach cancer) that have spread to other parts of the body (metastatic). Radiation therapy uses high-energy X-rays to kill cancer cells. You might be able to join if you are an adult with metastatic gastrointestinal cancer that is getting worse while you are already receiving immunotherapy (like a checkpoint inhibitor or CTLA4 inhibitor). The main goal is to see if radiation therapy can change your cancer's response from getting worse to becoming stable or shrinking. Researchers also want to see if treating one tumor with radiation can help your immune system fight other tumors in your body. This study plans to enroll 28 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 28 participants.
- What's involved
- You would undergo radiation therapy, which involves 5 treatments over 5-9 calendar days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your response to treatment will be measured for up to 8 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Mary Feng, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Overall response rate (ORR)Up to 8 weeks
Proportion of patients who achieve as their best overall response according to Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 criteria: Stable disease (SD), partial response (PR), confirmed Complete Response (CR), or progressive disease (PD). Corresponding exact confidence intervals will be reported for the entire cohort and stratified by histologic subtype, programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) status, microsatellite instability (MSI), and organs treated if sample size allows. Patients with unevaluable or unknown response status will be considered nonresponders.